An update in management of noncutaneous T-cell lymphomas

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Liang, R H S ^a   Hwang, Y Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; BORTEZOMIB; CD52 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; PRALATREXATE; PREDNISOLONE; ROMIDEPSIN; TUMOR MARKER; VINCRISTINE; VINDESINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LYMPHOMA;

EID: 79251538045     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/424786     Document Type: Review

References (42)

1. Swerdlow S. H., Campo E., Harris N. L., Mature T-cell and NK-cell neoplasms WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues 2008 Lyon, France International Agency for Research on Cancer 270 319
2. Gisselbrecht C., Gaulard P., Lepage E., Coiffier B., Brire J., Haioun C., Cazals-Hatem D., Bosly A., Xerri L., Tilly H., Berger F., Bouhabdallah R., Diebold J., Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe dEtudes des Lymphomes de lAdulte (GELA) Blood 1998 92 1 76 82
3. Cheng A.-L., Chen Y.-C., Wang C.-H., Su I.-J., Hsieh H.-C., Chang J.-Y., Hwang W.-S., Su W.-C., Liu T.-W., Tien H.-F., Tsai W., Shen M.-C., Liu C.-H., Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological gradesshould peripheral T-cell lymphoma be considered separately? Journal of Clinical Oncology 1989 7 6 725 731
4. López-Guillermo A., Cid J., Salar A., López A., Montalbn C., Castrillo J. M., Gonzlez M., Ribera J. M., Brunet S., Garca-Conde J., De Fernndez Sevilla A., Bosch F., Montserrat E., Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification Annals of Oncology 1998 9 8 849 855
5. Mourad N., Mounier N., Brire J., Raffoux E., Delmer A., Feller A., Meijer C. J. L. M., Emile J.-F., Bouabdallah R., Bosly A., Diebold J., Haioun C., Coiffier B., Gisselbrecht C., Gaulard P., Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe dEtude des Lymphomes de lAdulte (GELA) trials Blood 2008 111 9 4463 4470
6. Ascani S., Zinzani P. L., Gherlinzoni F., Sabattini E., Briskomatis A., De Vivo A., Piccioli M., Fraternali Orcioni G., Pieri F., Goldoni A., Piccaluga P. P., Zallocco D., Burnelli R., Leoncini L., Falini B., Tura S., Pileri S. A., Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification Annals of Oncology 1997 8 6 583 592
7. Vose J. M., Neumann M., Harris M. E., International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project Journal of Clinical Oncology 2008 26 25 4124 4130
8. Gascoyne R. D., Aoun P., Wu D., Chhanabhai M., Skinnider B. F., Greiner T. C., Morris S. W., Connors J. M., Vose J. M., Viswanatha D. S., Coldman A., Weisenburger D. D., Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma Blood 1999 93 11 3913 3921
9. Ten Berge R. L., Oudejans J. J., Ossenkoppele G.-J., Pulford K., Willemze R., Falini B., Chott A., Meijer C. J.L.M., ALK expression in extranodal anaplastic large cell lymphoma layouts systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination Journal of Clinical Pathology 2000 53 6 445 450
10. De Leval L., Gisselbrecht C., Gaulard P., Advances in the understanding and management of angioimmunoblastic T-cell lymphoma British Journal of Haematology 2010 148 5 673 689
11. Gallamini A., Stelitano C., Calvi R., Bellei M., Mattei D., Vitolo U., Morabito F., Martelli M., Brusamolino E., Iannitto E., Zaja F., Cortelazzo S., Rigacci L., Devizzi L., Todeschini G., Santini G., Brugiatelli M., Federico M., Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood 2004 103 7 2474 2479
12. Armitage J. O., Greer J. P., Levine A. M., Weisenburger D. D., Formenti S. C., Bast M., Conley S., Pierson J., Linder J., Cousar J. B., Nathwani B. N., Peripheral T-cell lymphoma Cancer 1989 63 1 158 163
13. Rdiger T., Weisenburger D. D., Anderson J. R., Armitage J. O., Diebold J., MacLennan K. A., Nathwani B. N., Ullrich F., Mller-Hermelink H. K., Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project Annals of Oncology 2002 13 1 140 149
14. Schmitz N., Trumper L., Ziepert M., Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Blood. In press
15. Escaln M. P., Liu N. S., Yang Y., Hess M., Walker P. L., Smith T. L., Dang N. H., Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center Experience Cancer 2005 103 10 2091 2098
16. Tilly H., Lepage E., Coiffier B., Blanc M., Herbrecht R., Bosly A., Attal M., Fillet G., Guettier C., Molina T. J., Gisselbrecht C., Reyes F., Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Blood 2003 102 13 4284 4289
17. Mounier N., Gisselbrecht C., Brire J., Haioun C., Feugier P., Offner F., Recher C., Stamatoullas A., Morschhauser F., Macro M., Thieblemont C., Sonet A., Fabiani B., Reyes F., Albin N., Allard C., Aoudjane M., Assouline D., Attal M., Audhuy B., Azagury M., Barats J. C., Beaumont C., Baumelou E., Biron P., Blanc M., Bordessoulle D., Bouabdallah R., Bouleuc C., Bourquard P., Bourquelot P., Bou F., Boulat O., Brice P., Brire J., Brun G., Caillot D., Casasnovas O., Carde P., Castaigne S., Chze S., Christian B., Colin P., Collet C., Conroy T., Cosnard T., Corront B., Cur H., Delmer A., Delwail V., Detourmignies L., Devidas A., Dombret H., Dor J. F., Doyen C., Dreyfus F., Dront S., Dupont G., Dupriez B., Eisenmann J. C., Fabbro M., Ferm C., Fillet G., Flesch M., Fruchart C., Gabarre J., Haioun C., Herbrecht R., Hermine O., Huyn A., Huguet F., Janvier M., Jourdan E., Karsenti J. M., Kerneis Y., Kohser F., Leblond V., Lederlin P., Lefort S., Lenain P., Lepeu G., Lepretre S., Levaltier X., Le Rol A., Marit G., Martin C., Mayer F., Nouvel C., Morel P., Moriceau M., Munck J. N., Nedellee G., Offner F., Pavlovitch J. M., Plantier I., Paud P. Y., Peny A. M., Pico J., Platini C., Pollet J. P., All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Annals of Oncology 2004 15 12 1790 1797
18. Nickelsen M., Ziepert M., Zeynalova S., Glass B., Metzner B., Leithaeuser M., Mueller-Hermelink H. K., Pfreundschuh M., Schmitz N., High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Annals of Oncology 2009 20 12 1977 1984
19. Rodrguez J., Conde E., Gutirrez A., Arranz R., Len., Marn J., Bendandi M., Albo C., Calballero M. D., The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience Annals of Oncology 2007 18 4 652 657
20. Rodrguez J., Conde E., Gutirrez A., Arranz R., Len., Marn J., Bendandi M., Albo C., Caballero M. D., Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group European Journal of Haematology 2007 79 1 32 38
21. Reimer P., Rdiger T., Geissinger E., Weissinger F., Nerl C., Schmitz N., Engert A., Einsele H., Muller-Hermelink H. K., Wilhelm M., Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: results of a prospective multicenter study Journal of Clinical Oncology 2009 27 1 106 113
22. Corradini P., Tarella C., Zallio F., Dodero A., Zanni M., Valagussa P., Gianni A. M., Rambaldi A., Barbui T., Cortelazzo S., Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation Leukemia 2006 20 9 1533 1538
23. Gallamini A., Zaja F., Patti C., Billio A., Specchia M. R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., Tarella C., Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood 2007 110 7 2316 2323
24. Zinzani P. L., Venturini F., Stefoni V., Fina M., Pellegrini C., Derenzini E., Gandolfi L., Broccoli A., Argnani L., Quirini F., Pileri S., Baccarani M., Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome Annals of Oncology 2009 21 4 860 863
25. Sallah S., Wan J. Y., Nguyen N. P., Treatment of refractory T-cell malignancies using gemcitabine British Journal of Haematology 2001 113 1 185 187
26. Kim J. G., Sohn S. K., Chae Y. S., Kim D. H., Baek J. H., Lee K. B., Lee J.-J., Chung I.-J., Kim H.-J., Yang D.-H., Lee W.-S., Joo Y.-D., Sohn C.-H., CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas Cancer Chemotherapy and Pharmacology 2006 58 1 35 39
27. Arkenau H.-T., Chong G., Cunningham D., Watkins D., Sirohi B., Chau I., Wotherspoon A., Norman A., Horwich A., Matutes E., Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience Haematologica 2007 92 2 271 272
28. Wang E. S., O'Connor O., She Y., Zelenetz A. D., Sirotnak F. M., Moore M. A. S., Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression Leukemia and Lymphoma 2003 44 6 1027 1035
29. Toner L. E., Vrhovac R., Smith E. A., Gardner J., Heaney M., Gonen M., Teruya-Feldstein J., Sirotnak F., O'Connor O. A., The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin's lymphoma Clinical Cancer Research 2006 12 3 924 932
30. O'Connor O. A., Horwitz S., Hamlin P., Portlock C., Moskowitz C. H., Sarasohn D., Neylon E., Mastrella J., Hamelers R., Macgregor-Cortelli B., Patterson M., Seshan V. E., Sirotnak F., Fleisher M., Mould D. R., Saunders M., Zelenetz A. D., Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies Journal of Clinical Oncology 2009 27 26 4357 4364
31. OConnor O., Pro B., Pinter-Brown L. L., Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Journal of Clinical Oncology 2009 27 15, supplement. abstract no. 8561
32. Piekarz R. L., Phase II trial of single agent romidepsin in relapsed peripheral T cell lymphoma Proceedings of the 50th Annual American Society of Hematology 2009. abstract no. 14157
33. Johnston P. B., Ansell S. M., Colgan J. P., mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with Everolimus (RAD001) Proceedings of the ASH Annual Meeting 2007 110. abstract no. 2555
34. Bartlett N. L., Younes A., Carabasi M. H., Forero A., Rosenblatt J. D., Leonard J. P., Bernstein S. H., Bociek R. G., Lorenz J. M., Hart B. W., Barton J., A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood 2008 111 4 1848 1854
35. D'Amore F., Radford J., Relander T., Jerkeman M., Tilly H., sterborg A., Morschhauser F., Gramatzki M., Dreyling M., Bang B., Hagberg H., Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma British Journal of Haematology 2010 150 5 565 573
36. Lee J., Suh C., Kang H. J., Ryoo B.-Y., Huh J., Ko Y. H., Eom H.-S., Kim K., Park K., Kim W. S., Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Annals of Oncology 2008 19 12 2079 2083
37. Horwitz S., Mulford D., Paul H., Clofarabine is active in peripheral T-cell lymphomas: results of the phase I portion of a phase I/II study Annals of Oncology 2008 19 supplement 4 iv157. abstract no. 244
38. Dueck G. S., Chua N., Prasad A., Activity of lenalidomide in a phase II trial for T-cell lymphoma: a report on the first 24 cases Journal of Clinical Oncology 2009 27 15, supplement. abstract no. 8524
39. Kyriakou C., Canals C., Finke J., Kobbe G., Harousseau J. L., Kolb H. J., Novitzky N., Goldstone A. H., Sureda A., Schmitz N., Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European Group for Blood and Marrow Transplantation Journal of Clinical Oncology 2009 27 24 3951 3958
40. Le Gouill S., Milpied N., Buzyn A., De Latour R. P., Vernant J.-P., Mohty M., Moles M.-P., Bouabdallah K., Bulabois C.-E., Dupuis J., Rio B., Gratecos N., Yakoub-Agha I., Attal M., Tournilhac O., Decaudin D., Bourhis J.-H., Blaise D., Volteau C., Michallet M., Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Socit Franaise de Greffe de Molle et de Thrapie Cellulaire Journal of Clinical Oncology 2008 26 14 2264 2271
41. Corradini P., Dodero A., Zallio F., Caracciolo D., Casini M., Bregni M., Narni F., Patriarca F., Boccadoro M., Benedetti F., Rambaldi A., Gianni A. M., Tarella C., Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells Journal of Clinical Oncology 2004 22 11 2172 2176
42. Shustov A. R., Gooley T. A., Sandmaier B. M., Allogeneic haematopoietic cell transplantation after non-myeloablative conditioning in patients with T-cell and natural killer-cell lymphoma British Journal of Haematology 2010 150 170 178